help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 9, 1018-1024, October 2006; doi:10.1634/theoncologist.11-9-1018
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Color...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, R. H.

Special Section on Colorectal Cancer

Novel Therapeutic Developments Other Than EGFR and VEGF Inhibition in Colorectal Cancer

Richard H. Wilson

Centre for Cancer Research and Cell Biology, Queen’s University, Belfast, Northern Ireland, United Kingdom

Key Words. Colorectal cancer • OSI-7904L • Pemetrexed • NB1011

Correspondence: Richard H. Wilson, M.D., Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast BT9 7AB, Northern Ireland, UK. Telephone: +44 (0)28 9026 3541; Fax: +44 (0)28 9026 3744; e-mail: r.wilson{at}qub.ac.uk

Developments that may improve existing cytotoxic therapy for colorectal cancer (CRC) include alternatives to 5-fluorouracil (5-FU) such as the liposomal Thymidylate Synthase inhibitor OSI-7904L and the multitargeted antifolate pemetrexed. Studies have explored means of reformulating irinotecan, modulating its pharmacokinetics, and enhancing its activity by maximizing DNA damage through poly(ADP-ribose) polymerase inhibition. Cell cycle inhibitors may offer an alternative to combination with 5-FU. However, as standard regimens become more complex, so do the clinical trials needed to develop new agents, and the path to registration becomes ever more tortuous. It is therefore likely that several drugs with promise in CRC will not be developed for this indication.




This article has been cited by other articles:


Home page
 The OncologistHome page
P. G. Johnston
The Colorectal Cancer Coalition: Reflections on the Future
Oncologist, October 1, 2006; 11(9): 970 - 972.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2006 by AlphaMed Press.